Ausgabe 5/2009
Inhalt (22 Artikel)
Erratum to: Genomic profiling of breast tumours in relation to BRCAabnormalities and phenotypes
Olafur Andri Stefansson, Jon Gunnlaugur Jonasson, Oskar Thor Johannsson, Kristrun Olafsdottir, Margret Steinarsdottir, Sigridur Valgeirsdottir, Jorunn Erla Eyfjord
Magnetic resonance imaging of the natural history of in situmammary neoplasia in transgenic mice: a pilot study
Sanaz A Jansen, Suzanne D Conzen, Xiaobing Fan, Erica J Markiewicz, Gillian M Newstead, Gregory S Karczmar
An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ
Fariba Behbod, Frances S Kittrell, Heather LaMarca, David Edwards, Sofia Kerbawy, Jessica C Heestand, Evelin Young, Purna Mukhopadhyay, Hung-Wen Yeh, D Craig Allred, Min Hu, Kornelia Polyak, Jeffrey M Rosen, Daniel Medina
Steroid Receptor RNA Activator Protein (SRAP): a potential new prognostic marker for estrogen receptor-positive/node-negative/younger breast cancer patients
Yi Yan, George P Skliris, Carla Penner, Shilpa Chooniedass-Kothari, Charlton Cooper, Zoann Nugent, Anne Blanchard, Peter H Watson, Yvonne Myal, Leigh C Murphy, Etienne Leygue
Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-β signaling and metastasis
Michael K Wendt, William P Schiemann
Key signalling nodes in mammary gland development and cancer. Mitogen-activated protein kinase signalling in experimental models of breast cancer progression and in mammary gland development
Jacqueline Whyte, Orla Bergin, Alessandro Bianchi, Sara McNally, Finian Martin
Development of 'synthetic lethal' strategies to target BRCA1-deficient breast cancer
Max S Wicha
Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy
Silvia Darb-Esfahani, Sibylle Loibl, Berit M Müller, Marc Roller, Carsten Denkert, Martina Komor, Karsten Schlüns, Jens Uwe Blohmer, Jan Budczies, Bernd Gerber, Aurelia Noske, Andreas du Bois, Wilko Weichert, Christian Jackisch, Manfred Dietel, Klaus Richter, Manfred Kaufmann, Gunter von Minckwitz
The membrane mucin MUC4 is elevated in breast tumor lymph node metastases relative to matched primary tumors and confers aggressive properties to breast cancer cells
Heather C Workman, Jamie K Miller, Ellen Q Ingalla, Rouminder P Kaur, Diane I Yamamoto, Laurel A Beckett, Lawrence JT Young, Robert D Cardiff, Alexander D Borowsky, Kermit L Carraway, Colleen Sweeney, Kermit L Carraway III
Comparative evaluation of cell-free tumor DNA in blood and disseminated tumor cells in bone marrow of patients with primary breast cancer
Heidi Schwarzenbach, Klaus Pantel, Birthe Kemper, Cord Beeger, Friedrich Otterbach, Rainer Kimmig, Sabine Kasimir-Bauer
Key signalling nodes in mammary gland development and cancer: Myc
Nancy E Hynes, Tina Stoelzle
Notch versus the proteasome: what is the target of γ-secretase inhibitor-I?
Anthony G Clementz, Clodia Osipo
Estrogen and progesterone receptors have distinct roles in the establishment of the hyperplastic phenotype in PR-A transgenic mice
Marina Simian, Mina J Bissell, Mary Helen Barcellos-Hoff, Gopalan Shyamala
Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer
Mark D Pegram, Virginia F Borges, Nuhad Ibrahim, Jyotsna Fuloria, Charles Shapiro, Susan Perez, Karen Wang, Franziska Schaedli Stark, Nigel Courtenay Luck
Update on the use of aromatase inhibitors in early-stage breast cancer
Georgios Kesisis, Andreas Makris, David Miles
BU-32: a novel proteasome inhibitor for breast cancer
Joseph K Agyin, Bindu Santhamma, Hareesh B Nair, Sudipa S Roy, Rajeshwar R Tekmal
Distinct inherited metastasis susceptibility exists for different breast cancer subtypes: a prognosis study
Szu-Min Hsieh, Maxime P Look, Anieta M Sieuwerts, John A Foekens, Kent W Hunter
Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers
Susan L Neuhausen, Sean Brummel, Yuan Chun Ding, Christian F Singer, Georg Pfeiler, Henry T Lynch, Katherine L Nathanson, Timothy R Rebbeck, Judy E Garber, Fergus Couch, Jeffrey Weitzel, Steven A Narod, Patricia A Ganz, Mary B Daly, Andrew K Godwin, Claudine Isaacs, Olufunmilayo I Olopade, Gail Tomlinson, Wendy S Rubinstein, Nadine Tung, Joanne L Blum, Daniel L Gillen
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
Richard S Finn, Judy Dering, Dylan Conklin, Ondrej Kalous, David J Cohen, Amrita J Desai, Charles Ginther, Mohammad Atefi, Isan Chen, Camilla Fowst, Gerret Los, Dennis J Slamon